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ABSTRACT Psoriasis severity varies by body region, with each affected re-
gion having a different impact on patient quality of life (Qol). the aim of this 
study was to assess the impact of changes in the Psoriasis Area and Severity 
Index (PASI) scores by body region on Qol in patients with psoriasis after 
treatment. A total of 100 patients with psoriasis were recruited to the study. 
All patients completed the generic EuroQol-5D instrument and two specific 
Qol measures, Dermatology life Quality Index (DlQI) and Psoriasis Disability 
Index (PDI) at the beginning of the study, and 50 patients successfully com-
pleted the same questionnaires four weeks after the end of the treatment. 
Clinical severity was assessed using PASI total score and PASI body region 
(head, trunk, arms, and legs) scores. Qol improved after treatment, and PASI 
improvements on visible body regions (head, legs, and arms) showed sig-
nificant correlation with the most sub-areas of the Visual Analog Scale (EQ 
VAS), DlQI, and PDI. Multiple linear regression analysis revealed that PASI 
improvement (particularly on the head), sex, age, and disease duration were 
predictors of Qol score changes for most domains of the three instruments. 
Improvement of psoriasis in visible body regions has an appreciable influ-
ence on Qol improvement, and may positively affect treatment success in 
patients with psoriasis. 
KEY WORDS: psoriasis, quality of life, psoriasis area and severity index, der-
matology life quality index, psoriasis disability index, EuroQol-5D
INTRODUCTION
Psoriasis is a chronic inflammatory skin disease 
characterized by redness, infiltrate, and scales. the 
severity of psoriasis can vary from small plaques lo-
calized in one part of the body to the involvement of 
the entire skin (1). Psoriasis has a negative impact on 
quality of life (Qol). Previous studies have described 
the ways in which psoriasis affects the lives of pa-
tients (2-5). Some studies were particularly focused 
on the relationship between psoriasis severity and 
Qol (6-8). the improvement of Qol has become the 
aim of many interventions (9-14). Psoriasis severity 
and treatment responsiveness vary by body region, 
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with each affected region having a different impact 
on patient Qol (9,15).
the aim of this study was to assess the impact of 
changes in PASI by body region on Qol in patients 
with psoriasis.
PATIENTS AND METHODS 
the study comprised 100 adult patients with plaque 
psoriasis treated at the Department of Dermatology, 
Clinical Centrе Zvezdara, Belgrade between January 
and December 2011. Patients younger than 18 years, 
newly diagnosed patients, and those with mental and 
other serious diseases (such as cancer, heart disease, or 
diabetes) were excluded from the study. Only patients 
who gave their written informed consent were recruit-
ed to the study. they were evaluated by experienced 
dermatologists who collected sociodemographic data 
(age, sex, education, and marital status) and disease 
characteristics (age at onset of disease and duration of 
disease). For the assessment of severity and extent of 
psoriasis and its response to treatment, the Psoriasis 
Area and Severity Index (PASI) was used. 
Each patient completed a generic Qol instrument 
(EuroQol-5D) and two specific Qol measures: the Der-
matology life of Quality index (DlQI) and the Psoria-
sis Disability Index (PID) at the beginning of the study, 
and 50 patients completed the same questionnaires 
successfully four weeks after the end of the treat-
ment. Another 50 patients were lost to follow-up (27 
did not attend the second assessment, and for 23 the 
questionnaires were discarded because they did not 
answer two and more questions per questionnaire). 
no significant differences were found between those 
who answered the questionnaire satisfactorily after 
treatment and those who did not regarding age, sex, 
marital status and education (data not shown). 
All patients were treated with psoralen plus ultra-
violet A (PUVA) photochemotherapy. PUVA therapy 
was administered according to the following proto-
col: two hours before the phototherapy, 8-methoxyp-
soralen was orally administered in a standard dose of 
0.6 mg/kg of body weight. the initial dose of UV ra-
diation was usually 0.5 J/cm2, and gradually increased 
by 0.25 J/cm2 to 1.5 J/cm2. Frequency of UV radiation 
was 2-4 times per week (typically 4 times per week), 
depending on the severity of psoriasis. 
the study was approved by the Ethics Commit-
tee of the School of Medicine, University of Priština, 
Kosovska Mitrovica, Serbia. 
Instruments 
PASI is a composite index used to measure the se-
verity and extent of psoriasis. It is aimed at assessing 
the overall severity of psoriasis as well as evaluating 
the severity of psoriasis in four regions of the body 
(head, trunk, arms and legs) (16,17). the severity of er-
ythema, infiltration, and desquamation were graded 
for each of four main body areas involved, resulting 
in ranges of total scores from 0 (the lowest score) to 
72 (the highest score), with higher scores indicating 
greater severity (16). In the present study, a total PASI 
score and PASI scores by body regions were assessed 
at baseline and after the end of the treatment.
EuroQol-5D (EQ-5D) is a generic health-related 
Qol instrument and was chosen to assess improve-
ment in Qol as subjects with psoriasis can suffer from 
multiple symptoms. the EQ-5D descriptive system 
consists of five questions − one question for each of 
the five dimensions that include mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depres-
sion. the respondents are required to rate their health 
by checking one of three levels of severity “no prob-
lems” (coded as 1), “some/moderate problems” (cod-
ed as 2), and “severe problems” (coded as 3) in each of 
the 5 EuroQol dimensions. the EQ-5D questionnaire 
also includes a Visual Analog Scale (EQ VAS), by which 
respondents can report their perceived health status 
on the day of administration with a grade ranging 
from 0 (the worst possible health status) to 100 (the 
best possible health status) (18). 
DlQI is a dermatology-specific 10-item question-
naire related to symptoms and feelings, daily activi-
ties, leisure, work and school, personal relationships, 
and treatment (19,20). It measures how much a skin 
problem has affected the life of patient over the pre-
vious week. the instrument consists of 10 items; DlQI 
is calculated by summing the score of each item, re-
sulting in a maximum of 30 and a minimum of 0. the 
higher the score, the more Qol is impaired. 
PDI is a psoriasis-specific 15-item questionnaire 
related to daily activities, work or school, personal 
relationships, leisure, and treatment effects during 
the preceding four weeks (21,22). the answers were 
scored from 0 to 3, producing a range of total PDI 
score from 0 to 45. the higher the score, the more 
Qol is impaired.
the validated and cross-culturally adapted Ser-
bian versions of the questionnaires showed good in-
ternal reliability across scales (Cronbach’s alpha coef-
ficient was 0.89 for DlQI and 0.87 for PDI).
Statistical analysis 
Categorical variables were expressed as counts 
and percentages. Continuous variables were present-
ed as mean ± Standard Deviation (SD). Mann-Whitney 
U-test was used to analyze changes from the time of 
Sojević timotijević et al. Acta Dermatovenerol Croat
PASI and QOl in psoriasis patients    2017;25(3):215-222
217ACTA DERMATOVENEROLOGICA CROATICA
hospital admission to 4 weeks after discharge. to ver-
ify how EQ-5D, DlQI and PDI changes in scores cor-
related with sex, age, disease duration, and changes 
in disease severity (total PASI score and PASI by body 
region), we used the Spearman’s rho (ρ) correlation 
coefficient. 
Multiple linear regression analyses were carried 
out to examine the association of demographic (sex 
and age) and clinical characteristics (duration of dis-
ease and severity of disease) with changes in EQ-5D, 
DlQI, and PDI scores after treatment. A two-tailed 
probability value of P< 0.05 was considered statistical-
ly significant. All statistical analyses were performed 
using SPSS software (Statistical Package for the Social 
Sciences Inc., Chicago, Il, USA, Version 19.0). 
In the present study, EQ-5D, DlQI, and PDI were 
assessed at baseline and four weeks after the end of 
the treatment.
RESULTS 
the sociodemographic and clinical character-
istics of patients who satisfactorily completed all 
three questionnaires at baseline and four weeks af-
ter the end of the treatment (n = 50) are presented in 
table 1. 
there were more women (62%) than men (38%), 
and most of them were married (66%). Half of all pa-
tients had secondary education (50%), and a quarter 
had an university degree (26%). Mean age at onset of 
disease was approximately 33 years, and mean age 
at inclusion in the study was approximately 47 years. 
Mean duration of the disease was 13.9±9.6 years.
table 2 shows mean Qol and PASI scores and 
their mean percentage changes for 50 patients who 
completed all questionnaires at both assessments: 
at baseline and four weeks after the end of the treat-
ment. Significant improvements after treatment were 
observed in overall PASI score and regional PASI scores 
(head, trunk, arms, and legs). the mean scores in EQ-
5D, DlQI, and PDI in all their domains also showed sta-
tistically significant improvements. the mean percent-
age change from baseline to week 4 after the end of 
the treatment in EQ VAS, overall DlQI, and overall PDI 
scores, were 97.6%, − 78.6%, and − 70.1% respectively.
table 3 displays the correlations between chang-
es in Qol, sex, age, disease duration, and changes in 
disease severity measured by Spearman correlation 
coefficients.
the strongest correlation was found between 
changes in DlQI domain symptoms and feelings and 
total PASI score (ρ = 0.53), between changes in DlQI 
symptoms and feelings and PASI on the legs (ρ = 
0.53), followed by high correlation between changes 
in total DlQI and total PASI score (ρ = 0.52), total DlQI 
and PASI changes on the legs (ρ = 0.49), as well be-
tween changes in DlQI symptoms and feelings and 
PASI changes on the arms (ρ = 0.48). Changes in PDI 
daily activities and in total PDI score also correlated 
highly with PASI score changes on the head (ρ = 0.57 
and 0.52, respectively). In the EQ-5D scale, the stron-
gest correlation was found between changes in EQ 
VAS and disease severity on the head (ρ = − 0.45).
Significant, but weak correlation was found be-
tween changes in Qol (EQ-5D anxiety/depression 
and EQ VAS) and sex, Qol (DlQI daily activities and 
PDI leisure) and age, and Qol (EQ-5D usual activity 
and pain/discomfort) and disease duration.
Analyzing the results of multiple regression analy-
sis (table 4) found some evidence that a relationship 
between disease site and the degree of Qol impair-
ment existed. the correlation coefficients between 
changes in Qol (for PDI daily activities, EQ VAS, PDI 
total score, and DlQI leisure) and changes in disease 
severity over the head were among the highest coef-
ficients found (0.54, − 0.45, 0.43, and 0.36, respective-
ly). there was a similar relationship between changes 
in PDI work or school domain and DlQI symptoms 
and feelings and changes in disease severity on the 
legs (0.49 and 0.36, respectively). 
Statistically significant, but weak correlations 
were found between changes in EQ-5D anxiety/de-
pression and sex (0.31) and EQ VAS and sex (− 0.31). 
Improvements were observed for men.
Changes in PDI domain leisure and DlQI domain 
daily activities positively correlated with age (0.45 
Table 1. Sociodemographic and clinical charac-
teristics of the patients with psoriasis who com-





Mean age at inclusion ± SD (year) 46.7±13.4 
Mean age at onset of disease ± SD (year) 32.8±14.5 




Elementary school 3 (6)
Secondary school 25 (50)
Higher school 9 (18)
University degree 13 (26)
Mean duration of disease ± SD (year) 13.9±9.6 
*SD: Standard Deviation
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and 0.33, respectively). A positive correlation was also 
found between disease duration and EQ-5D pain/dis-
comfort (0.39). Persons with shorter disease duration 
reported higher improvements in pain/discomfort. 
DISCUSSION
the present study assessed the impact of changes 
in PASI score (total and for body regions) on Qol in 
patients with psoriasis at baseline and four weeks 
after the end of the treatment using three validated 
Qol questionnaires (EQ-5D, DlQI, and PDI) simulta-
neously. 
PASI is the most commonly used tool to assess the 
severity of psoriasis and treatment effects. However, it 
has several limitations, including the following: score 
calculation is complex, the amount of affected body 
surface area is a subjective estimate, and the amount 
of improvement in the score does not always corre-
spond to clinical relevance. Additionally, the scoring 
does not take into account the impact on patient Qol 
or the disproportionate psoriasis burden reflected in 
the more visible (face, neck, hands, feet) or covered 
(genitalia) body regions (23). 
In most studies, data on changes in Qol were ana-
lyzed in relation to changes in total PASI scores (11,14), 
while only a few studies analyzed them in relation to 
the changes in PASI scores across body regions (9,15). 
In a recently published study, the importance of the 
use of PASI score by body region was highlighted and 
recommended as a novel and important patient-rel-
evant outcome worthy of reporting in future studies 
(23). this was the reason that we evaluated the im-
pact of changes in PASI body regions on Qol, rather 
than only changes in total PASI score.
Table 2. Mean quality of life (Qol) and Psoriasis Area and Severity Index (PASI) scores at baseline and four weeks after the 
end of the treatment for patients with both assessments (n = 50)
    Baseline   After treatment 
    Mean ± SD  Mean ± SD  % change* 
EQ-5D    
  Mobility      1.3±0.5     1.1 ±0.3   − 16.9
  Self-care     1.2±0.4     1.0±0.1   − 15.0
  Usual activities     1.7±0.7     1.1±0.3   − 36.8
  Pain/Discomfort     2.0±0.5     1.3±0.5   − 36.3
  Anxiety/Depression    2.1±0.6     1.5±0.5   − 29.9
  EQ VAS    40.2±24.5  79.5±16.6       97.6
DlQI    
  Symptoms and feelings    3.7±1.4     1.0±1.0   − 73.0
  Daily activities     3.1±1.4     0.6±1.0   − 82.1
  leisure      2.5±1.8     0.4±0.7   − 83.7
  Work or school     1.6±1.3     0.2±0.7   − 84.8
  Personal relationships    1.4±1.8     0.3±1.8   − 72.8
  treatment      1.6±1.0     0.4±0.6   − 72.8
  total score   13.9±6.5     3.0±4.0   − 78.6
PDI    
  Daily activities     8.1±3.5     2.7±2.3   − 66.1
  Work or school     3.2±2.4     0.5±1.1   − 83.8
  Personal relationships    1.7±1.8     0.6±1.7   − 63.9
  leisure      2.9±2.3     0.9±1.5   − 68.5
  treatment      1.3±1.0      0.4±0.5   − 71.9
  total score   16.9±8.6     5.1±4.7   − 70.1
PASI    
  Head      1.2±1.2     0.2±0.2   − 82.6
  trunk      4.0±3.4     0.7±0.9   − 81.4
  Arms      3.2±2.5     0.5±0.5   − 83.5
  legs      7.8±5.2     1.5±1.3   − 80.3
  total    16.2±10.9    3.0±2.4   − 81.3
*All % changes were statistically significant at P<0.05.
SD: Standard Deviation; EQ-5D: EuroQol 5D; DlQI: Dermatology  
life Quality Index; PDI: Psoriasis Disability Index; PASI: Psoriasis Area and Severity Index; EQ VAS: Visual Analog 
Scale
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Our findings show that the most important pre-
dictor of improving the Qol measured by all three 
instruments after applied therapy and within the four 
body regions in PASI is the improvement of psoria-
sis on the head. As in the study by touw et al. (9), we 
found that the severity of psoriasis not only on the 
head, but also on the arms and legs have a greater 
impact on Qol than the severity of the disease on the 
trunk. this indicates that involvement of visible areas 
of the body causes greater impairment of Qol than 
involvement of unseen areas. Our results are in accor-
dance with previous studies showing that social vis-
ibility of psoriasis is associated with higher impact on 
Qol (3,9,15,22,24).
Although the head represents only 10% of the total 
body surface, the visibility of head and neck psoriasis 
has a considerable impact on patient Qol. When pso-
riasis involves the face, it can be much more disabling, 
inducing important social and emotional distress, and 
can severely decrease Qol (25). Additionally, the effect 
of clinical improvement on psychological improve-
ment in patients with localization on the face was 
weaker than in the other cases (25). However, Richards 
et al. observed that grouping of patients on the basis 
of head involvement was not an optimal strategy for 
the assessment of observable, cosmetically disfiguring 
psoriasis and its effect on psychosocial factors, which 
were much stronger determinants of disability in pa-
tients with psoriasis than disease severity (8).
the improvement of the disease over the arms and 
legs in our study was a significant predictor of Qol im-
provement for the DlQI work or school domain, EQ-5D 
usual activities (arms), DlQI symptoms and feelings, 
and PDI work or school domain (legs). this may indi-
cate that the treatment of patients with psoriasis is not 
sufficient to improve the overall burden experienced 
by them. Such information once again emphasizes 
the fact that even clearance of psoriasis, although it 
produces a significant reduction in factors specific to 
psoriasis, such as disability and stress, does not impact 
psychological distress, on patient beliefs about psoria-
sis, or coping (11).
Table 3. Correlation coefficients between changes in quality of life and sex, age, disease duration, and chang-
es in disease severity 
PASI 
Quality of life Sex† Age
Disease 
duration
Head Arms trunk legs total score
EQ-5D
  Mobility − 0.18     0.09     0.11     0.04     0.01 − 0.03     0.20     0.13
  Self-care − 0.04     0.22     0.21 − 0.04 − 0.09 − 0.11 − 0.05 − 0.07
  Usual activities     0.12     0.12     0.29*     0.23     0.29*     0.14     0.15     0.19
  Pain/Discomfort     0.06 − 0.06     0.34*     0.19     0.14     0.16     0.06     0.15
  Anxiety/Depression     0.28* − 0.02 − 0.03     0.16     0.15     0.17     0.06     0.12
  EQ VAS − 0.36* − 0.06     0.10 − 0.45* − 0.20 − 0.33* − 0.24 − 0.36*
DlQI
  Symptoms and feelings    0.24     0.24     0.02     0.39*     0.48*     0.38*     0.53*     0.53*
  Daily activities    0.23     0.38* − 0.02     0.47*     0.34*     0.34*     0.30*     0.39*
  leisure    0.27     0.14 − 0.09     0.45*     0.28*     0.32*     0.36*     0.38*
  Work or school    0.05     0.16     0.22     0.30*     0.44*     0.22     0.44*     0.43*
  Personal relationships    0.17     0.12 − 0.17     0.26     0.24     0.22     0.36*     0.34*
  treatment    0.10     0.19     0.03     0.13     0.11     0.14     0.19     0.22
  total score    0.25     0.28     0.01     0.47*     0.43*     0.36*     0.49*     0.52*
PDI
  Daily activities    0.18     0.04 − 0.04     0.57*     0.33*     0.37*     0.37*     0.45*
  Work or school    0.17     0.05     0.12     0.31*     0.32*     0.28*     0.44*     0.42*
  Personal relationships    0.20     0.12     0.01     0.32*     0.17     0.18     0.32*     0.31*
  leisure    0.06     0.40* − 0.14     0.21     0.03     0.00     0.13     0.11
  treatment    0.02 − 0.17 − 0.24     0.22     0.07     0.12     0.08     0.10
  total score    0.19     0.16 − 0.05     0.52*     0.29*     0.30*     0.41*     0.43*
*Statistically significant correlation coefficients (P<0.05). †Male is the reference category.
EQ-5D: EuroQol 5D; DlQI: Dermatology life Quality Index; PDI: Psoriasis Disability Index; PASI: Psoriasis Area and Severity 
Index; EQ VAS: Visual Analog Scale
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PASI body regions (head, trunk, upper and lower 
extremities) are not the only localizations used for the 
evaluation of the relationship between changes in 
psoriasis severity and Qol. the involvement of other 
areas of the body was used in several studies (e.g. only 
genital region or face) (12,26). However, the results of 
these studies did not indicate whether the body re-
gions covered by PASI in comparison with other lo-
calizations have advantages or disadvantages in the 
assessment of disease severity.
the association between symptom severity and 
Qol was observed in a number of studies (2,7,27,28). 
However, some studies found no significant associa-
tion at all (4,5,29). A likely explanation is that symp-
tom severity has a greater impact on the physical 
than on the mental components of Qol, whereas the 
effects of stigmatization on Qol are more strongly 
mental (30).
In our study, disease duration had a negative 
impact on Qol improvement only for EQ-5D pain/
discomfort. lee et al. found that disease duration of 
more than 10 years had a negative impact on Qol 
score changes (31).
Among demographic factors, sex and age proved 
to be predictors of improvement of Qol in our study. 
Studies generally show no sex/gender difference in 
the severity of physical symptoms of psoriasis in men 
and women. However, women and men have differ-
ent subjective perceptions of how psoriasis affect their 
social and emotional life and Qol. Perceived stress was 
higher in women, and the mental component of their 
Qol was more altered (32). the men in our study were 
more likely to report improvement in health status 
assessed by EQ VAS, and psychological improvement 
assessed by EQ-5D (anxiety/depression) after clini-
cal improvement measured by PASI. Similarly, Samp-
ogna et al. observed that the improvement in clinical 
severity and symptoms was associated with a de-
creased frequency of psychiatric disturbance and that 
men were more likely to improve psychologically in 
Table 4. Standardized regression coefficients in multiple linear regression models of predictors associated 
with EuroQol 5D (EQ-5D), Dermatology life Quality Index (DlQI), and Psoriasis Disability Index (PDI) score 
changes 
PASI 
Quality of life Sex† Age
Disease 
duration
Head Arms trunk legs
EQ-5D
  Mobility − 0.10     0.05     0.07
  Self-care     0.00     0.14     0.16
  Usual activities     0.10 − 0.04     0.25     0.28*
  Pain/Discomfort     0.16 − 0.16     0.39*
  Anxiety/Depression     0.31* − 0.01     0.10
  EQ VAS − 0.31* − 0.03     0.01 − 0.45*     0.07
DlQI
  Symptoms and feelings     0.09     0.22 − 0.02     0.09     0.12 − 0.08 0.36*
  Daily activities     0.14     0.33* − 0.10     0.22     0.05     0.01 0.04
  leisure     0.14     0.06 − 0.08     0.36* − 0.10 − 0.02 0.21
  Work or school − 0.13     0.01     0.16     0.07     0.33* 0.28
  Personal relationships     0.07     0.11 − 0.07 0.21
  treatment     0.12     0.19     0.05
  total score     0.11     0.19 − 0.03     0.25     0.08 − 0.09 0.30
PDI
  Daily activities     0.09     0.00 − 0.05     0.54* − 0.17     0.02 0.07
  Work or school     0.04 − 0.05     0.18     0.06     0.04 − 0.07 0.49*
  Personal relationships     0.14 − 0.02     0.07     0.34* 0.01
  leisure     0.01     0.45* − 0.21
  treatment − 0.07 − 0.10 − 0.18
  total score     0.11     0.09 − 0.01     0.43* − 0.18 − 0.16 0.34
*Statistically significant correlation coefficients (P<0.05). †Male is the reference category.
EQ-5D: EuroQol 5D; DlQI: Dermatology life Quality Index; PDI: Psoriasis Disability Index; PASI: Psoriasis Area and Severity 
Index; EQ VAS: Visual Analog Scale
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comparison with women (12). In contrast to our study, 
in several other studies found no significant associa-
tion between sex and with Qol (4,31), or Qol was more 
seriously affected in women than in men (33).
the results of the current study demonstrated 
that the improvement of Qol (DlQI daily activities 
and PDI leisure) after clinical improvement was high-
er in younger than in older patients, which is in accor-
dance with Sampogna et al. (34) who found that the 
impact of psoriasis is more severe for older patients 
over 65 years of age. In contrast, Young found that 
the impact of psoriasis seems to be more severe for 
young adults (35).
the present study also showed that EQ-5D was 
less sensitive to the changes in severity of psoriasis 
compared with DlQI and PDI instruments. the expla-
nation may be that EQ-5D captures health-related 
Qol across diseases, whereas DlQI and PDI are de-
signed to measure skin-specific and psoriasis-specific 
Qol rather than generic Qol.
Our study is one of the few studies (9,15) in which 
the relationship between changes in Qol and regional 
disease severity has been examined. In addition, data 
on the differences of impairment by dimensions of EQ-
5D, DlQI, and PDI offer new insight. However, some 
limitations of the study have to be considered. the first 
one refers to the relatively small number of patients 
who completed all questionnaires after treatment. Sec-
ond, the Qol instruments applied in the study do not 
include assessment of stress and specific psychologi-
cal aspects. third, we did not consider the potential ef-
fect of behavior factors, such as alcohol consumption, 
cigarette smoking, and use of antidepressants on Qol.
CONCLUSION
the current study has shown that the effect of 
improving Qol in psoriasis varies between PASI body 
regions. In particular, the reduction of psoriasis on 
the head is associated with the highest Qol improve-
ment in overall wellbeing, daily activities, and leisure, 
while the improvement of psoriasis on the arms and 
legs is important for the improvement of symptoms 
and feelings and work or school. Our findings dem-
onstrate that significant clinical improvements in re-
gional psoriasis severity correlated with meaningful 
improvements in Qol and support the importance of 
Qol assessment in terms of better understanding of 
patient response to treatment. 
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